A new clinical trial is evaluating selinexor, a non-JAK inhibitor, as a first-line therapy in myelofibrosis, with a JAK inhibitor added later only if needed. This innovative sequencing challenges the current, long-standing paradigm of initiating all treatments with a JAK inhibitor.

A proactive clinical practice is to refer all newly diagnosed myelofibrosis patients for a transplant consultation, irrespective of their initial risk score. This preemptive step helps overcome significant logistical delays in finding a suitable donor, which is particularly crucial for patients from diverse ethnic backgrounds where donor availability is limited.

Clinicians can reassure myelofibrosis patients that the drop in hemoglobin often seen when starting ruxolitinib does not carry the same negative prognostic weight as anemia caused by the disease itself. This distinction is crucial for managing patient expectations and continuing effective therapy despite initial side effects.

For myelofibrosis patients with profound splenomegaly but only moderate thrombocytopenia (platelets 50k-100k), fedratinib may be the best frontline option. It is arguably the most potent JAK inhibitor for spleen reduction and is approved for use in patients with platelet counts as low as 50,000.

Interferon therapy is being evaluated in a distinct niche from JAK inhibitors. It is targeted at patients with early or low-risk myelofibrosis, not for immediate symptom control, but with the strategic goal of potentially modifying the disease course and slowing its natural progression.

A critical challenge in myelofibrosis care is that the optimal time for a curative transplant is when patients feel well, often due to effective JAK inhibitor therapy. This feeling of well-being makes them reluctant to undergo the high-risk procedure. Waiting until they feel sick makes the transplant less likely to succeed.

For myelofibrosis patients with both anemia and splenomegaly, a practical approach is to start with ruxolitinib for its superior symptom control. If the subsequent anemia is not well-tolerated, switching to momelotinib allows for a more informed, personalized decision based on the patient's experience with both agents.

In the era of potent targeted therapies for Philadelphia chromosome-positive B-ALL, the most critical factor for deciding on a consolidative allogeneic stem cell transplant is persistent minimal residual disease (MRD). This response-based metric has become more important than baseline mutational status for upfront risk stratification and treatment planning.

Based on findings from the DETERMINATION-1 and MIDAS trials, which questioned the overall survival benefit of early transplant, new strategies are emerging. The DETERMINATION-2 trial will use iberdomide-based therapy and defer transplant for standard-risk, MRD-negative patients, reserving it for higher-risk cases.